Jessica Kachadourian

Heart Failure / Cardiomyopathy

Intellia Therapeutics (United States)

About

Jessica Kachadourian works in Heart Failure / Cardiomyopathy affiliated with Intellia Therapeutics (United States).

Jessica Kachadourian, Pharm.D., is affiliated with Intellia Therapeutics in the United States. She has co-authored publications on the PARADIGM-HF trial results regarding sacubitril/valsartan and on CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy. She was previously associated with Novartis Pharmaceuticals.

Research focus

Sacubitril/Valsartan therapy in heart failureCRISPR-Cas9 gene editing for ATTR cardiomyopathyLoop diuretic use in heart failure patientsHypotensive episodes in heart failure managementATTR amyloidosis with cardiomyopathy and polyneuropathy

Impact

6 pubs · 381 cites · h-index 5

Training

Pharm.D.
Northeastern University, School of Pharmacy

Affiliations

Work Experience

Intellia Therapeutics

Novartis